CJC-1295 (no DAC), also referred to as Modified GRF (1–29), in combination with Ipamorelin, constitutes a dual-peptide research formulation composed of two mechanistically distinct growth hormone secretagogues. Within experimental frameworks, this combination is utilized to investigate coordinated modulation of the growth hormone (GH) axis through complementary receptor-mediated pathways. CJC-1295 (no DAC) functions as an analog of growth hormone–releasing hormone (GHRH), selectively engaging GHRH receptors to stimulate intracellular cAMP accumulation and downstream protein kinase A (PKA)–dependent signaling associated with GH synthesis. In contrast, Ipamorelin acts as a selective agonist of the ghrelin receptor (GHS-R1a), initiating Gq/11-coupled signaling cascades that elevate intracellular calcium levels and promote GH release dynamics.
In preclinical and in vitro models, this peptide combination is frequently employed to examine GH pulsatility, receptor cross-talk, and the integrated regulation of hypothalamic–pituitary signaling networks. Quantifiable endpoints such as hormone secretion kinetics, receptor activation profiles, and intracellular signaling responses enable detailed characterization of peptide-mediated endocrine modulation under controlled laboratory conditions, without extrapolation to human therapeutic outcomes.
For research use only. Not for human consumption.
References:
Bowers CY et al., Endocrinology, 1990 126(2):1165–1171
Teichman SL et al., J Clin Endocrinol Metab, 2006 91(2):479–487
Kojima M et al., Nature, 1999 402(6762):656–660
Reviews
There are no reviews yet.